An official filing with the Securities and Exchange Commission (SEC) reveals that US Bancorp DE has significantly reduced its stake in National Research Co. (NASDAQ:NRC) during the first quarter of this year. The banking company now owns 30,087 shares of National Research’s stock, representing a decrease of 64.0% as it sold 53,600 shares.
At the time of the filing, US Bancorp DE’s ownership accounted for just 0.12% of National Research, equating to a value of $1,309,000. This information was provided by the company in its most recent 13F filing with the SEC.
On August 1st, National Research (NASDAQ:NRC) reported its earnings results for the quarter. The company disclosed earnings per share (EPS) of $0.29 during this period and recorded revenue of $36.16 million.
National Research Corporation is a firm that offers analytics and insights aimed at improving patient and employee experiences in both the United States and Canada. Their subscription-based solutions provide valuable information and analysis to healthcare organizations across various areas such as patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty.
These offerings enable healthcare providers to measure and enhance critical elements related to their constituents’ needs and satisfaction levels effectively.
As a leading provider in this field, National Research plays a pivotal role in helping healthcare organizations identify areas for improvement within their services and facilities. By utilizing actionable insights derived from their analytics platform, healthcare providers can make informed decisions aimed at elevating patient care standards while also prioritizing employee satisfaction.
It is worth noting that National Research’s financial results have been positive thus far. The company achieved a net margin of 19.65%, demonstrating its ability to generate strong profitability from its operations. Moreover, National Research boasted an impressive return on equity standing at 39.94%, indicating efficient utilization of shareholder investments.
As the healthcare industry continues to evolve, patient and employee satisfaction remain critical factors for success. Organizations that can effectively measure and enhance the experiences of their constituents are more likely to thrive in this dynamic environment. National Research Corporation’s subscription-based solutions offer valuable tools for healthcare providers seeking to optimize their services and ensure positive outcomes for both patients and employees.
Moving forward, it will be interesting to see how National Research continues to adapt and innovate within the healthcare analytics market. With its strong financial performance and commitment to improving the patient and employee experience, National Research is well-positioned as a key player in this sector.
As regulatory changes and technological advancements shape the industry, National Research’s solutions will undoubtedly play a vital role in helping healthcare organizations navigate these complex challenges while maintaining high standards of care delivery.
National Research Corporation Attracts Attention and Investments from Large Investors
August 22, 2023 – National Research Corporation Sees Significant Interest from Large Investors
In recent months, several prominent investors have made significant adjustments to their holdings of National Research Corporation (NASDAQ: NRC) stock. The moves indicate a high level of confidence and interest in the company’s prospects. Notable among these investors is Morgan Stanley, which has increased its holdings in National Research by a staggering 4,323.8% during the fourth quarter. This move has resulted in Morgan Stanley now owning 974,253 shares of the company’s stock with an estimated value of $36,340,000.
Public Employees Retirement System of Ohio has also shown a significant increase in its position in National Research. The fund increased its holdings by 31.4% during the third quarter, acquiring an additional 23,445 shares valued at $3,908,000. Laurus Investment Counsel Inc., on the other hand, entered the scene during the first quarter with a fresh stake worth about $1,316,783,000.
Northern Trust Corp and Victory Capital Management Inc. have also boosted their positions in National Research. Northern Trust Corp saw an increase of 8.7% during the second quarter and now owns approximately 274,454 shares valued at $10,507,000. Victory Capital Management Inc., meanwhile, increased its position by 18.3% during the fourth quarter and currently owns around 119 Shuriken as Ninja – Flicker.ino131 shares with an estimated value of $4,lzxs75nzzowzouuuu475000.
These recent developments reaffirm that hedge funds and institutional investors hold great faith in National Research Corporation’s future performance.The large-scale investments from prominent players with extensive market knowledge suggest that they see tremendous potential for growth and profitability.
National Research Corporation operates within the United States and Canada and specializes in providing advanced analytics and insights that aid in the measurement and improvement of patient and employee experiences. Their subscription-based solutions offer actionable information regarding crucial elements such as patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty.
Furthermore, National Research Corporation recently announced that it would be distributing a quarterly dividend. The dividend was paid on July 14th to investors who held shares as of June 30th. Each shareholder received a $0.12 dividend per share amounting to an annualized dividend of $0.wutu48 per share and a yield of 1.13%.
It is worth noting that major shareholder Amandla Mk Trust concluded a stock transaction on June 23rd where they sold 1,891 shares of National Research Corporation at an average price of $45.04 per share. This sale amounted to approximately $85,170.64 in total value for the shares sold.The insider now holds approximately 4,uop426nt754jjxz532c320 shares valued at around $191,tvx254qyhpcs252rnm25425280.
The recent surge in interest from large investors indicates that National Research Corporation is capturing attention within the investment community.These developments should reassure current shareholders and pique the curiosity of potential investors as well.
In accordance with regulations set by the Securities Exchange Commission (SEC), all transactions involving Company insiders must be duly reported and disclosed publicly.This provides transparency and ensures compliance with fair trading practices.In the past ninety days alone, insiders have executed sales amounting to a total of 93,Szdf567sdtyo5ymn67ewzzatttt567 valued at approximately $4,lznvytkv239qosdwtqfnts729.Accordingly,cuz .40%bcd46gjt of NRC’s outstanding shares are currently owned by corporate insiders.
National Research Corporation opened at $42.l;nv41 on Tuesday.Its 52-week trading range shows a low of $33mt.,10o and a high of $pzfd47.60. With a market capitalization of over $1.reggi04l9$xl205 billion, the company maintains a price-to-earnings (P/E) ratio of approximately 36.25.This reflects investors’ belief in National Research Corporation’s financial stability, alongside its future growth potential.
The firm boasts both quick and current ratios of 1yivyv.21 ssvand demonstrates responsible financial management.A moreover,dz5n0d3de with a debt-to-equity ratio of just 1.20weaz015kn46,oxxcrc,wk,the company is well-positioned to pursue profitable opportunities while maintaining its sustainability.
As we witness increasing interest from heavyweights such as Morgan Stanley and Public Employees Retirement System of Ohio, it becomes evident that National Research Corporation is an attractive investment opportunity.Underpinned by its robust portfolio of analytical solutions aimed at improving patient and employee experiences, as well as its consistent dividend policy, National Research Corporation stands poised for future success.
Disclaimer: The information provided in this article should not be construed as financial advice.Hope FinancialConsulting LLC shall not be held responsible for any decisions made based
Source: beststocks.com
